Quality Standard of Compound Quanchangning Capsule

[ Objective] The research aimed to study the quality standard of Compound Quanchangning Capsule. [ Method] Coptis, Phelledendron, Pulsatilla and Astragalus in Compound Quanchangning Capsule were indentified qualitatively by thin layer chromatography （ TLC）, and the content of berberine hydrochloride was determined by high performance liquid chromatography （HPLC）, to study the quality standard of Compound Quanchangning Capsule. [ Result] TLC identification showed that the tested product was clear and well-separated with no interference. Berberine hydrechloride showed a good linear relationship with peak area at the injection volume of 10.92 - 163.74 ~Lg/mL, and the regression equation was Y = 39 611X -2 387. 9 （R2 = 0. 999 8） ; the average recovery was 97.60%, and the relative standard deviation was 1.64% （n =6）. [ Conclusion] The standard is simple in operation and good in specificity, stability and repeatability, which is prompted as a favorable method for quality control of Compound Quanchangning Capsule.

Meta-analysis and Trial Sequential Analysis of Compound Qingdai Capsule in the Treatment of Psoriasis

[Objectives]To analyze the efficacy of Compound Qingdai Capsule in the treatment of psoriasis and conduct a systematic evaluation.[Methods]The clinical total effective rate,PASI index score,IL-17 level,IL-23 level,TNF-level,and adverse reactions were analyzed.TSA 0.9 software was used to conduct sequential analysis of the total effective rate,and subgroup analysis was performed according to the average age of the experimental group.[Results]Single application of Compound Qingdai Capsule or in combination with other methods in the treatment of psoriasis was superior to non-Compound Qingdai Capsule group,and the side effects were less than non-Compound Qingdai Capsule group;the n≥40 year-old group had certain heterogeneity,suggesting that the difference was statistically significant,and the effective rate was higher than that of the control group.The funnel plot showed that the graph was asymmetrical,and there may be publication bias or the possibility of low-quality literature.The TSA results indicated that the actual sample size was far lower than the expected sample size,and the cumulative Z value did not reach the TSA cut-off value and more trials need to be included to confirm the efficacy.[Conclusions]Compound Qingdai Capsule has a clear curative effect on psoriasis,and its safety is high.This study can provide relevant evidence for the effectiveness of Chinese patent drugs(CPD)in treating psoriasis.

Validation of Microbial Limit Test Methods of Compound Gangbangui Capsule

[Objectives] This study was conducted to establish a method for microbial limit test of Compound Gangbangui Capsule. [Methods] According to the Chinese Pharmacopoei 2015 edition of the four general rules,the microbiological limits of non-sterile products were verified. [Results]Compound Gangbangui Capsule has a strong inhibitory effect on S. aureus,and the antimicrobial activity was significantly eliminated after increasing the diluent（ 1∶ 20）; and the recoveries were in the range of 0. 5-2. 0 when the total quantities of aerobic microbes were determined by dilution method（ 1∶ 20）. When the total quantities of mould and yeast were determined by conventional method（ 1∶ 20）,the recoveries were from 0. 5 to 2. 0,and Escherichia coli can be detected in experimental groups by the test solution dilution method. [Conclusions]With the plate method,the total quantities of aerobic bacteria and the quantities of mould and yeast were examined by increasing diluent and conventional method,respectively,and control bacteria,E. coli was examined by conventional method. This method has been proved effective for microbial limit test of Compound Gangbangui Capsule,and can effectively control the quality of the preparation. The method is accurate and reliable.

Molecular mechanism of Compound Qingdai Capsule in the treatment of psoriasis based on network pharmacology and molecular docking

Objective:Although Compound Qingdai Capsule(CQC)successfully treats psoriasis,the exact mechanism remains unclear.Our research used network pharmacology to investigate the molecular mechanism of CQC in treating psoriasis.Methods:The Traditional Chinese Medicine Systems Pharmacology platform was used to screen the bioactive chemical elements and identify gene targets,and the ingredient-target network was visualized by Cytoscape software.Genes associated with psoriasis were found in the Gene Expression Omnibus database.The protein-protein interaction network was created using STRING and Cytoscape,and the hub genes were identified using MCODE and topological analysis.Gene ontology and Kyoto encyclopedia of genes and genomes analyses were applied to obtain hub genes’biological processes and signaling pathways.Subsequently,the ingredient-target-pathway-disease network was visualized by Cytoscape.Results:Finally,an active ingredient-target network of CQC containing 130 active ingredients and 213 targets was built.Conclusion:The top 3 bioactive components were identified as quercetin,luteolin,and kaempferol,and the top 5 hub genes were identified as IL1B,CXCL8,STAT3,MMP9,and HMOX1.The critical pathways of CQC treatment in psoriasis were AGE-RAGE signaling,IL-17 signaling,TNF signaling,Fluid shear stress and atherosclerosis,and Toll-like receptor signaling pathway.Molecular docking confirmed a robust binding affinity between the main active ingredients of CQC with the hub target proteins.On this basis,additional animal or cellular research might be undertaken to investigate the targets and mechanisms of CQC treatment in psoriasis.

Clinical Effect of Laser Treatment Combined with Compound Xueshuantong Capsule in the Treatment of Diabetic Retinopathy

Objective:To determine the clinical value of compound Xueshuantong capsule in the treatment of diabetic retinopathy on the basis of laser treatment.Methods:Data were collected from 98 patients with diabetic retinopathy from February 2021 to February 2022.They were divided into two groups by drawing lots.The experimental group was treated with compound Xueshuantong capsule and laser treatment,whereas the control group was treated with laser treatment alone.Results:The absorption of exudation,resolution of retinal edema,and absorption of bleeding took longer in the control group;the incidence of visual acuity recovery to more than 0.5 and the patients’blood glucose levels were better in the experimental group,p<0.05.Conclusion:For patients with diabetic retinopathy,laser treatment combined with compound Xueshuantong capsule can effectively improve the visual function and rehabilitation efficiency of patients with diabetic retinopathy as well as stabilize their blood sugar levels.It has high clinical application value.

Mechanism of Erhuang capsule for treatment of multiple sclerosis

Erhuang capsule, a typical formula based on traditional Chinese medicine theory, is widely used to ameliorate multiple sclerosis, inflammation and side effects of glucocortJcoid treatment. Oligodendrocyte precursor cells are neural stem cells that are important for myelin repair and regeneration. In the present study, Erhuang capsule effectively improved clinical symptoms and neurological function scores, reduced mortality and promoted recovery of neurological functions of mice with experimental autoimmune encephalomyelitis. The mechanism of action involved significant increases in oligodendrocyte precursor cell proliferation in specific regions of the brain and spinal cord, increased oligodendrocyte lineage gene 2 expression and enhanced oligodendrocyte precursor cell differentiation.

Experimental Study on the Repair Effect of Xianlinggubao Capsule on Osteoporotic Vertebral Compression Fracture in Rabbits

[Objectives]To observe the effect of Xianlinggubao Capsule on osteoporotic vertebral compression fracture(OVCF)in rabbits and the influence mechanism of the repair of fractures.[Methods]Female June age 30 rabbits were randomly divided into control group,model control group and Xianlinggubao group.After bilateral ovariectomy,the model control group and Xianlinggubao group were injected with dexamethasone continuously for 4 weeks,and then the OVCF compound model was established by surgery.The Xianlinggubao group was treated with Xianlinggubao at a dose of 300 mg/(kg·d)for 60 d,while the blank control group and the model control group were treated with the same amount of normal saline for 60 d.The number of blood vessels and the expression of bone morphogenetic protein-2(BMP-2)were detected by immunohistochemical staining and the bone mineral density(BMD)in the callus of the third lumbar fracture area of rabbits was measured.The content of serum phosphorus(P),alkaline phosphatase(ALP)and total calcium(TCa)in rabbit venous blood were measured by automatic biochemical analyzer.The content of vascular endothelial growth factor(VEGF)and platelet-derived growth factor(PDGF)in rabbit venous blood were measured by ELISA kit.[Results]The number of blood vessels and the expression of BMP-2 in the callus of the third lumbar fracture area of rabbits was high in Xianlinggubao group,the content of serum P,ALP,TCa,VEGF and PDGF was obviously increased,BMD was obviously increased,the bone microstructure of the third lumbar vertebrae fracture area of rabbits was basically restored.Compared with the model control group(P<0.05),the difference was statistically significant.[Conclusions]Xianlinggubao Capsule can increase calcium and phosphorus deposition,promote the formation of blood vessels in the fracture area of OVCF in rabbits,and have a strong repair effect on OVCF in rabbits.

Meta-analysis on Efficacy and Safety of Compound Stomachache Inflammation Caused by Helicobacter Pylori

Objective:To systematically evaluate the efficacy and safety of Compound Stomachache Capsule(复方胃痛胶囊)in the treatment of digestive ulcer and inflammation Helicobacter pylori-Peptic Ulcer(Hp-PU)caused by Helicobacter pylori(Hp).Methods:Randomized controlled trials(RCTs)of Compound Stomachache Capsule(复方胃痛胶囊)in the treatment of Hp-PU were screened out by searching CNKI,VIP,Wanfang,China Biomedical Literature Service System,Cochrane Library,Pub Med,EMbase,Web of Science and Clinical Trials.gov.Meta-analysis was performed with Rev Man 5.4 software.Results:Three RCTs were included,including 331 patients of 166 patients in the experimental group(Compound Stomachache Capsule(复方胃痛胶囊)+conventional western medicine treatment)and 165 patients in the control group(conventional western medicine treatment).Meta-analysis data showed that Hp eradication rate(RR=1.10,95%CI[1.01-1.19],P=0.03)was significantly higher in the experimental group than in the control group.The experimental group was superior to the control group in improving clinical symptoms(RR=1.59,95%CI[1.22-2.06],P=0.0006).Conclusion:According to the current evidence,the Compound Stomachache Capsule(复方胃痛胶囊)combined with conventional Western medicine treatment can improve the Hp eradication rate of Hp-PU,relieve symptoms,and do not increase the incidence of adverse reactions.However,the number of included studies is small and the sample size is small,so its effectiveness and safety need further verification.

羟丙基淀粉植物胶囊的研究

以羟丙基淀粉(HPS)为主料,羧甲基纤维素钠(CMC-Na)和海藻酸钠(SA)为增强剂,并辅以凝胶剂和塑化剂,制备了复合植物胶囊HPS/CMC-Na/SA,采用单因素实验和正交实验优化了制备工艺,并通过SEM、FTIR、XRD对其进行表征。结果表明,当HPS加量为85 mg·mL^(-1)、CMC-Na加量为8.5 mg·mL^(-1)、SA加量为4.5 mg·mL^(-1)时,复合植物胶囊的抗拉强度为30.08 MPa,断裂伸长率为14.49%,杨氏模量为1289.77 MPa,800 nm透光率为78.068%,400 nm透光率为63.072%。

灵芝螺旋藻复方胶囊辅助降血糖功能

该文探究灵芝螺旋藻复方胶囊对Ⅱ型糖尿病小鼠的降血糖作用。采用高热能饲料结合腹腔注射链脲佐菌素的方法,建立Ⅱ型糖尿病小鼠模型,随机将小鼠分为对照组、模型组和低、中、高剂量组。灵芝螺旋藻复方胶囊连续干预4周,测定小鼠体质量、脏器指数、血液相关指标并观察肝、胰腺、盲肠病理组织切片。结果显示,低、中、高剂量(相当于人体推荐用量5、10、30倍)灵芝螺旋藻复方胶囊能不同程度改善糖尿病小鼠脏器指数、血糖水平以及葡萄糖耐量;从病理组织切片观察到经过3个剂量组干预的肝细胞体积明显恢复且排列整齐、脂滴空泡减少,肝细胞的损伤与炎症明显改善;胰岛细胞边界随剂量的增大而变得逐渐清晰且有序;低、中剂量两个组除绒毛有少部分呈圆状环绕外,3个剂量组盲肠组织外膜、肌层、黏膜、绒毛形态均有明显改善。综上,低、中、高3个剂量灵芝螺旋藻复方胶囊均可有效改善Ⅱ型糖尿病小鼠的糖脂代谢,有助于维持血糖健康水平。

复方红豆杉胶囊维持治疗气虚痰瘀证晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究

目的:探讨复方红豆杉胶囊维持治疗气虚痰瘀证晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效和安全性。方法:采用多中心、大样本、前瞻性队列研究方法,纳入一线化疗4~6周期后疗效评价疾病稳定以上进入维持治疗阶段患者,根据患者意愿分为治疗组160例,对照组109例。对照组根据鳞癌和非鳞癌分别给予吉西他滨和培美曲塞单药化疗维持治疗,治疗组给予复方红豆杉胶囊维持治疗。均以21天为1个疗程,两组干预至少2个疗程,每周期进行生活质量评价,每2疗程进行影像学疗效评价。比较两组疾病无进展生存时间(progression-free survival time,PFS)、生活质量,同时进行药物安全性评价。结果:269例入组患者中,246例患者出现PFS终点事件(91.45%),其中治疗组145例,中位PFS为106天,对照组101例,中位PFS为120天,两组PFS比较差异无统计学意义(P>0.05)。采用美国肺癌生存质量量表(FACT-L4.0版)和欧洲五维健康量表中视觉模拟量表(EQ-5D-VAS)对两组患者生活质量评分进行比较,两种生活质量评价量表均提示治疗组较对照组在提高生活质量方面存在优势(P<0.05)。治疗期间两组共有19例患者出现ADR,治疗组7例(占治疗组人数4.38%),对照组12例(占对照组人数11.01%),ADR发生率在治疗组中更低,尤其表现在骨髓抑制不良反应的发生率方面。结论:在延长PFS方面,复方红豆杉胶囊维持治疗气虚痰瘀证晚期NSCLC的疗效非劣于现代医学单药维持化疗,且在高生活质量、低不良反应方面,复方红豆杉胶囊更具有一定优势。

温针灸联合复方雪莲胶囊治疗强直性脊柱炎对软骨代谢和炎性反应的影响

目的探讨温针灸联合复方雪莲胶囊治疗强直性脊柱炎对软骨代谢和炎性反应的影响。方法选取医院2020年6月至2022年6月收治的强直性脊柱炎患者178例,按治疗方案的不同分为对照组和观察组,各89例。两组患者均予温针灸治疗,观察组患者加服复方雪莲胶囊。两组均连续治疗2个月。结果观察组总有效率为95.51%,显著高于对照组的85.39%(P<0.05)。两组患者治疗后的巴氏强直性脊柱炎疾病活动指数(BASDAI)评分、巴氏强直性脊柱炎功能指数(BASFI)评分、视觉模拟量表(VAS)评分均显著降低,枕墙距、指地距均显著缩小,腰椎活动度均显著改善,血清软骨寡聚基质蛋白、白细胞介素35、肿瘤坏死因子-α、C反应蛋白、白细胞介素2及白细胞介素17的表达水平均显著降低,且观察组改善程度更显著(P<0.05)。观察组患者治疗后的腰背疼痛、关节水肿、关节疼痛、晨僵缓解时间均显著短于对照组(P<0.05)。观察组不良反应发生率为4.49%,显著低于对照组的10.11%(P<0.05)。结论温针灸联合复方雪莲胶囊治疗强直性脊柱炎,能有效缓解患者的临床症状,减轻关节疼痛,抑制炎性反应,降低血清炎性因子表达水平。

复方万年青胶囊联合化疗对中晚期非小细胞肺癌患者辅助性T细胞17/调节性T细胞失衡和血清凋亡因子的影响

目的 探讨复方万年青胶囊联合吉西他滨+顺铂(GP)化疗方案对中晚期非小细胞肺癌(NSCLC)患者辅助性T细胞17(Th17)/调节性T细胞(Treg)失衡和血清凋亡因子的影响。方法 选择2018年3月至2021年2月西安医学院第一附属医院收治的98例中晚期NSCLC患者。按照随机数字表法将患者分为对照组和观察组,各49例。对照组接受GP化疗方案治疗;观察组在对照组基础上联合复方万年青胶囊口服治疗。以21 d为1个疗程,完成4个疗程的化疗。比较2组临床疗效以及治疗前后血清Th17、Treg、Th17/Treg比值、肿瘤标志物水平、凋亡因子水平。观察2组治疗期间不良反应发生情况。所有患者随访2年,记录无进展生存期(PFS)和总生存期。结果 治疗后,观察组客观缓解率和疾病控制率均高于对照组(均P<0.05)。治疗后,2组Treg均低于治疗前、且观察组低于对照组[(2.9±0.5)%比(4.8±0.8)%],2组Th17、Th17/Treg比值均高于治疗前、且观察组均高于对照组[(1.42±0.13)%比(1.25±0.11)%、(0.49±0.10)比(0.26±0.08)](均P<0.05);2组癌胚抗原、细胞角蛋白19片段、糖类抗原125、B淋巴细胞瘤基因2(Bcl-2)水平均低于治疗前、且观察组均低于对照组,2组Bcl-2相关X蛋白水平均高于治疗前、且观察组高于对照组(均P<0.05)。2组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。观察组中位PFS、中位总生存期均长于对照组(均P<0.01)。结论 复方万年青胶囊联合GP化疗方案治疗中晚期NSCLC患者,可有效控制疾病进展,延长生存期,调节血清肿瘤标志物和血清凋亡因子水平,改善免疫功能。

“温阳祛瘀”中药熏洗联合复方益母草胶囊对阳虚血瘀型子宫复旧不全产妇早期康复的临床研究

目的:研究分析“温阳祛瘀”中药熏洗联合复方益母草胶囊对阳虚血瘀型子宫复旧不全产妇早期康复的临床效果。方法:前瞻性纳入2021年4月—2023年4月在广东省人民医院赣州医院妇产科住院的阳虚血瘀型子宫复旧不全产妇80例,将患者按照随机数字表法分为治疗组(n=40)和对照组(n=40)。对照组在常规治疗的基础上加用复方益母草胶囊,治疗组在对照组基础上加以“温阳祛瘀”中药熏洗治疗。比较两组临床症状消失时间、子宫恢复情况、疼痛情况、睡眠质量、心理状态、临床疗效。结果:治疗组恶露、腹痛消失时间均早于对照组,子宫底高度、子宫体积均小于对照组,子宫腔积液量少于对照组,视觉模拟评分法(VAS)、抑郁自评量表(SDS)、焦虑自评量表(SAS)、匹兹堡睡眠质量指数(PSQI)评分均低于对照组,临床疗效优于对照组,差异均有统计学意义(P<0.05)。结论:“温阳祛瘀”中药熏洗联合复方益母草胶囊能显著促进阳虚血瘀型子宫复旧不全产妇早期康复,有效提高产妇睡眠质量,改善不良情绪,整体治疗效果较佳。

基于正交设计探讨复方蕨麻胶囊对低温低氧失血性休克大鼠微循环的影响

[目的]基于正交设计,探究不同条件(空气氧含量、环境温度及药物浓度)对失血性休克(HS)大鼠微循环的影响,为预防低温低氧HS提供最优方案。[方法]本研究选取海拔(用空气氧含量模拟)[3551.7 m(13.5%)、3080.7 m(14.5%)、2751 m(15.2%)]、环境温度(5~10℃、10~15℃、15~20℃)及药物浓度[复方蕨麻胶囊低(27 mg/kg)、中(54 mg/kg)、高(81 mg/Kg)剂量]三个因素,每个因素各选取三个水平,采用三因素三水平的正交设计,按照L9(34)正交表进行实验,共得出9种组合。将27只350~400 g雄性SD大鼠根据正交设计的干预方案分为9组,每组重复3次,进行HS大鼠的造模。实验过程中采集并记录放血前(T)、复苏前(T0)、复苏后1 h(T1)、复苏后2 h(T2)、复苏后3 h(T3)、复苏后4 h(T4)、复苏后5 h(T5)共7个时间点的平均动脉压(MAP)、心率(HR)、肠系膜微循环指标[包括血管流速、灌注血管密度(PVD)和微循环血流指数(MFI)]。采用相关的统计学方法进行分析,先筛选出实验最佳观测时间点,而后选出本实验条件下对改善HS大鼠的最优方案。[结果]筛选实验最佳观测时间点:对9组大鼠的MAP、HR、肠系膜流速七个时间点进行比较。1)MAP:①各组大鼠的MAP在不同时间点变化趋势一致(F=1.471,P=0.051);②组间差异无统计学意义(F=1.002,P=0.467);③各组MAP在不同时间点不全相等(F=417.804,P<0.001)。2)HR:①各组大鼠的HR在不同时间点变化趋势一致(F=0.782,P=0.730);②组间差异无统计学意义(F=0.647,P=0.729);③各组HR在不同时间点不全相等(F=947.477,P<0.001)。3)肠系膜血管流速:①各组大鼠的肠系膜流速在不同时间点变化趋势不同(F=4.933,P<0.001);②组间流速差异无统计学意义(F=2.141,P=0.086);③各组T在不同时间点不全相等(F=82.425,P<0.001)。4)小结:根据以上数据选定T1为最佳实验观测点。本实验条件下最优方案的选择:①改善血管流速的最佳组合为第二组;②改善PVD的最佳组合为第二组;③改善MFI的最佳组合为第二组;④小结:第二组(即氧含量13.5%、温度10~15℃、药物浓度为中剂量)在实验条件内的组合最佳。[结论]HS大鼠复苏后的五个观察点内,T1这个时间点各指标改善最优;复方蕨麻胶囊中剂量对3500 m左右的HS大鼠复苏效果最佳。

复方苁蓉益智胶囊治疗轻中度血管性痴呆

目的探讨复方苁蓉益智胶囊治疗轻中度血管性痴呆的临床疗效及对患者各临床检测指标的影响。方法选择2022年9月-2023年5月收治的轻中度血管性痴呆患者140例,随机分为对照与治疗组,各70例。对照组给予银杏叶提取物注射液治疗,治疗组在对照组基础上联合复方苁蓉益智胶囊治疗。比较2组临床疗效结果,治疗前后认知、神经功能、精神行为症状、血液流变学、血流动力学、应激反应指标、血清血管内皮生长因子(VEGF)、脑源性神经营养因子(BDNF)、基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-2(MMP-2)水平变化,比较2组不良反应发生情况。结果治疗组治疗6个月后临床疗效总有效率(95.71%,67/70)高于对照组(78.57%,55/70)(P<0.05)。2组治疗6个月后MMSE评分、大脑前动脉平均血流速度、中动脉平均血流速度及血清SOD、VEGF、BDNF水平高于治疗前(P<0.05),治疗组高于对照组(P<0.05);2组治疗6个月后NIHSS、NPI-Q评分、全血低切黏度、全血高切黏度、血浆黏度及血清MDA、Caspase-12、CRP78、MMP-9、MMP-2水平代于治疗前(P<0.05),治疗组低于对照组(P<0.05)。治疗组治疗不良反应总发生率低于对照组(P<0.05)。结论复方苁蓉益智胶囊治疗轻中度血管性痴呆患者临床疗效较好,安全性较高。

藿朴夏苓汤合桑菊饮加减治疗感染后咳嗽临床观察

目的 观察藿朴夏苓汤合桑菊饮加减治疗感染后咳嗽(湿热型邪郁肺卫证)的临床疗效及安全性。方法 采用随机数字表法将患者120例分为对照组与观察组各60例。对照组予以口服复方甲氧那明胶囊,观察组予以霍朴夏苓汤合桑菊饮加减,治疗7 d后,观察两组患者治疗前后的咳嗽症状积分、中医证候积分、生活质量评分、临床疗效、不良反应。结果 两组患者治疗后的咳嗽症状评分、中医证候积分均较前显著下降(P <0.05),观察组下降更为明显(P <0.05)。两组生活质量评分均较治疗前提高(P <0.05),观察组显著高于对照组(P <0.05);观察组的总有效率为93.33%,高于对照组的78.33%(P> 0.05),两组不良反应差异无统计学意义(P> 0.05)。结论 藿朴夏苓汤合桑菊饮加减可以有效提高感染后咳嗽(湿热型邪郁肺卫证)患者的临床疗效,且无明显不良反应。

同时测定复方四维女贞子胶囊中维生素B_(1)和维生素B_(6)的含量

目的:建立高效液相色谱法测定复方四维女贞子胶囊中维生素B_(1)和维生素B_(6)的含量。方法:采用C 18(4.6 mm×250 mm,5μm)色谱柱,以乙腈-庚烷磺酸钠溶液(0.32 g庚烷磺酸钠,加水800 mL溶解,加三乙胺2 mL,冰醋酸10 mL,加水稀释至1000 mL)(体积比7∶93)为流动相,流速:1.0 mL/min,检测波长:274 nm,柱温为40℃,进样体积10μL。结果:维生素B_(1)在0.4988~99.76μg范围内线性关系良好,回归方程Y=12976x-2190.4(R 2=1);维生素B_(6)在0.4822~96.44μg范围内线性关系良好,回归方程Y=11071x+1567(R 2=1);维生素B_(1)回收率为100.76%(n=9),RSD为0.7%;维生素B_(6)回收率为99.51%(n=9),RSD为0.8%。结论:该方法简便、快速、准确,为复方四维女贞子胶囊中维生素B_(1)和维生素B_(6)的含量测定提供了科学的测定方法。

复方青黛胶囊联合左西替利嗪治疗玫瑰糠疹的临床疗效及对Th17/Treg细胞平衡的影响

目的探讨复方青黛胶囊联合左西替利嗪治疗玫瑰糠疹的临床疗效及安全性。方法选择2022年1—12月于本院就诊的96例玫瑰糠疹患者作为研究对象,随机分为对照组和治疗组两组,每组各48例。对照组给予盐酸左西替利嗪片口服,1次/d,1片/次;治疗组在对照组的基础上口服复方青黛胶囊,3次/d,4粒/次。两组均治疗3周。比较两组临床疗效、PRSS评分、体征和症状至少缓解50%所需时间、血清IL-17、IL-22和IL-10的表达水平及不良反应发生率的差异。结果治疗后,与对照组相比,治疗组总有效率明显升高,差异具有统计学意义(P=0.037)。治疗后与对照组相比,治疗组PRSS评分[(2.37±0.28)vs.(3.22±0.85),P<0.05]明显降低。与对照组相比,治疗组皮疹数目[(8.56±2.01)vs.(10.25±2.91),P<0.05]、红斑[(7.42±1.28)vs.(9.63±1.55),P<0.05]、厚度[(6.22±1.17)vs.(7.40±1.35),P<0.05]、鳞屑[(4.55±1.04)vs.(6.26±1.33),P<0.05]和瘙痒感[(5.22±1.67)vs.(7.68±2.39),P<0.05]至少减轻50%所需时间均有所降低。治疗后与对照组相比,治疗组IL-17[(24.01±4.34)vs.(54.33±8.75),P<0.05]及IL-22[(69.76±12.23)vs.(95.45±14.32),P<0.05]表达水平明显降低,而IL-10[(132.12±22.23)vs.(92.12±19.45),P<0.05]表达水平明显升高。对照组和治疗组治疗期间不良反应发生率分别为16.67%和14.58%,不良反应发生率相比较无显著差异(P=0.779)。结论复方青黛胶囊联合盐酸左西替利嗪片治疗玫瑰糠疹的临床疗效明显,能快速且有效改善患者的皮损和瘙痒感,可能机制与改善Th17/Treg细胞平衡有关。

复方斑蝥胶囊联合旋转容积调强技术对头颈部放疗生存期及血清XRCC1、XRCC3mRNA水平的影响

目的探究复方斑蝥胶囊联合旋转容积调强技术对头颈部放疗患者生存期及血清X线修复交错互补基因1(X-ray Repair Cross Complementing 1,XRCC1)、X线修复交错互补基因3(X-ray Repair Cross Complementing 3,XRCC3)信使核糖核酸(Messenger RNA,mRNA)水平的影响。方法选取2019年6月—2021年7月医院收治的头颈部肿瘤患者97例作为研究对象,根据治疗方法不同进行分组,对照组(48例)采用旋转容积调强技术结合放疗治疗,联合组(49例)在对照组基础上加用复方斑蝥胶囊治疗。观察比较临床疗效、中医证候积分、血清XRCC1及XRCC3mRNA水平、生存期、不良反应。结果联合组客观缓解率高于对照组(P<0.05),但疾病控制率与对照组比较差异无统计学意义(P>0.05)。联合组自汗、恶心呕吐、神疲乏力、食欲差、失眠、头晕眼花等得分低于对照组(P<0.05)。联合组血清XRCC1、XRCC3水平及外周血XRCC1、XRCC3 mRNA表达均低于对照组(P<0.05)。联合组无进展生存期和总生存期均高于对照组(P<0.05)。联合组不良反应发生率(34.69%,17/49)低于对照组不良反应发生率(72.92%,35/48)(P<0.05)。结论复方斑蝥胶囊联合旋转容积调强技术能改善头颈部放疗患者肿瘤客观缓解率,缓解临床症状,降低血清XRCC1、XRCC3mRNA水平,减少不良反应。